Identifying Gaps in Respiratory Syncytial Virus Disease Epidemiology in the United States Prior to the Introduction of Vaccines | Zendy

Lindsay Kim | Zendy; Brian Rha | Zendy; Jon S. Abramson | Zendy; Larry J. Anderson | Zendy; Carrie L. Byington | Zendy; Grace Chen | Zendy; John P. DeVincenzo | Zendy; Kathryn M. Edwards | Zendy; Janet A. Englund | Zendy; Ann R. Falsey | Zendy; Marie R. Griffin | Zendy; Ruth A. Karron | Zendy; Karen G Martin | Zendy; H. Cody Meissner | Zendy; Flor M. Muñoz | Zendy; Andrew T. Pavia | Zendy; Pedro A. Piedra | Zendy; William Schaffner | Zendy; Eric A. F. Simões | Zendy; Rosalyn Singleton | Zendy; H. Keipp Talbot | Zendy; Edward E. Walsh | Zendy; Jane R. Zucker | Zendy; Susan I. Gerber | Zendy

Open Access

Identifying Gaps in Respiratory Syncytial Virus Disease Epidemiology in the United States Prior to the Introduction of Vaccines

Author(s) -

Lindsay Kim,

Brian Rha,

Jon S. Abramson,

Larry J. Anderson,

Carrie L. Byington,

Grace Chen,

John P. DeVincenzo,

Kathryn M. Edwards,

Janet A. Englund,

Ann R. Falsey,

Marie R. Griffin,

Ruth A. Karron,

Karen G Martin,

H. Cody Meissner,

Flor M. Muñoz,

Andrew T. Pavia,

Pedro A. Piedra,

William Schaffner,

Eric A. F. Simões,

Rosalyn Singleton,

H. Keipp Talbot,

Edward E. Walsh,

Jane R. Zucker,

Susan I. Gerber

Publication year - 2017

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/cix432

Subject(s) - medicine , epidemiology , respiratory tract infections , disease control , intensive care medicine , disease , family medicine , virology , immunology , pediatrics , respiratory system , psychiatry

Respiratory syncytial virus (RSV) causes lower respiratory tract illness frequently. No effective antivirals or vaccines for RSV are approved for use in the United States; however, there are at least 50 vaccines and monoclonal antibody products in development, with those targeting older adults and pregnant women (to protect young infants) in phase 2 and 3 clinical trials. Unanswered questions regarding RSV epidemiology need to be identified and addressed prior to RSV vaccine introduction to guide the measurement of impact and future recommendations. The Centers for Disease Control and Prevention (CDC) convened a technical consultation to gather input from external subject matter experts on their individual perspectives regarding evidence gaps in current RSV epidemiology in the United States, potential studies and surveillance platforms needed to fill these gaps, and prioritizing efforts. Participants articulated their individual views, and CDC staff synthesized individuals' input into this report.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research